Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 11-12, 2012, Pages 1076-1083

  Tay, C Y ^a   Windsor, H M ^a   Thirriot, F ^a   Lu, W ^a   Conway, C ^a   Perkins, T T ^a   Marshall, B J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; BISMUTH CITRATE; CIPROFLOXACIN; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ALLERGY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AUSTRALIA; BACTERIUM CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT DURATION; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG COMBINATION; ISOLATION AND PURIFICATION; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RIFABUTIN; TREATMENT OUTCOME; WESTERN AUSTRALIA; YOUNG ADULT;

EID: 84875880718     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12089     Document Type: Review

References (66)

1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
2. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 2005;81:419-24. (Pubitemid 41002579)
3. Ma X, Yu H. Global burden of cancer. Yale J Biol Med 2006;79:85-94.
4. Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am 2005;89:313-44, viii. (Pubitemid 40126820)
5. Malaty HM. Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007;21:205-14. (Pubitemid 46421909)
6. Khalifa M, Sharaf R, Aziz R. Helicobacter pylori: a poor man's gut pathogen? Gut Pathog 2010;2:2.
7. Carrasco-Garrido P, Jimenez-Garcia R, Barrera V, de Andres A, de Miguel A. Significant differences in the use of healthcare resources of native-born and foreign born in Spain. BMC Public Health 2009;9:201.
8. Lin SK, Lambert JR, Nicholson L, Lukito W, Wahlqvist M. Prevalence of Helicobacter pylori in a representative Anglo-Celtic population of urban Melbourne. J Gastroenterol Hepatol 1998;13:505-10. (Pubitemid 28258952)
9. Robertson MS, Cade JF, Savoia HF, Clancy RL. Helicobacter pylori infection in the Australian community: current prevalence and lack of association with ABO blood groups. Intern Med J 2003;33:163-7. (Pubitemid 36628241)
10. De Francesco V, Giorgio F, Hassan C, et al. Worldwide Helicobacter pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14.
11. Megraud F. Helicobacter pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84. (Pubitemid 39120130)
12. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2012; doi: 10.1136/gutjnl-2012-302254.
13. Gibney KB, Mihrshahi S, Torresi J, Marshall C, Leder K, Biggs BA. The profile of health problems in African immigrants attending an infectious disease unit in Melbourne. Australia. Am J Trop Med Hyg 2009;80:805-11.
14. Malfertheiner P, Megraud F, O'Morain C, et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997;9:1-2. (Pubitemid 27047348)
15. Raymond J, Lamarque D, Kalach N, Chaussade S, Burucoa C. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010;15:21-7.
16. Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 2010;8:59-70.
17. Debets-Ossenkopp YJ, Herscheid AJ, Pot R G J, Kuipers EJ, Kusters JG, Van Den Broucke-Grauls C M J E. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999;43:511-5. (Pubitemid 29182300)
18. Cabrita J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000;46:1029-31. (Pubitemid 32000618)
19. Windsor HM, Abioye-Kuteyi EA, Marshall BJ. Methodology and transport medium for collection of Helicobacter pylori on a string test in remote locations. Helicobacter 2005;10:630-4. (Pubitemid 41668350)
20. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. Wayne, PA: National Committee for Clinical Laboratory Standard, 2000.
21. Australian Bureau of Statistics, 2011. Australian Demographic Statistics, cat. no. 3101. 0. Available at: http://www.abs. gov. au/. Accessed February 20, 2012.
22. Mohammadi M, Doroud D, Massarrat S, Farahvash MJ. Clarithromycin resistance in iranian Helicobacter pylori strains before introduction of clarithromycin. Helicobacter 2003;8:80-80.
23. Mendonça S, Ecclissato C, Sartori MS, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in brazil. Helicobacter 2000;5:79-83. (Pubitemid 34951164)
24. Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011;27:565-70.
25. Taylor DE, Ge Z, Purych D, Lo T, Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother 1997;41:2621-8. (Pubitemid 27524731)
26. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996;40:477-80. (Pubitemid 26049364)
27. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995;39:107-11.
28. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999;43:1497-9. (Pubitemid 29259353)
29. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten S J O, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 1998;28:383-93. (Pubitemid 28182260)
30. Jenks PJ, Ferrero RL, Labigne A. The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 1999;43:753-8. (Pubitemid 29273724)
31. Miendje Deyi VY, Bontems P, Vanderpas J, et al. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol 2011;49:2200-9.
32. Sanchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Tito L, Castro M. Tenday sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008;103:2220-3.
33. De Francesco V, Giorgio F, Ierardi E, et al. Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. J Gastrointestin Liver Dis 2011;20:235-9.
34. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs.quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:553-60. (Pubitemid 36384814)
35. Borody TJ, Pang G, Wettstein AR, et al. Efficacy and safety of rifabutincontaining 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:481-8. (Pubitemid 43382002)
36. Bayerdorffer E, Mannes GA, Sommer A, et al. High-dose omeprazole treatment combined with amoxicillin eradicates Helicobacter-pylori. Eur J Gastroenterol Hepatol 1992;4:697-702.
37. Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacterpylori infection in patients with duodenal-ulcers. Gastroenterology 1995;108:1412-7.
38. Viiala CH, Windsor HM, Marshall BJ. Cure rate of high dose omeprazole and amoxicillin therapy for treatmentresistant Helicobacter pylori infection. J Gastroenterol Hepatol 2005;20:663-4. (Pubitemid 40755291)
39. Dore MP, Tadeu V, Are B, et al. Efficacy of a "Rescue" ciprofloxacinbased regimen for eradication of Helicobacter pylori infection after treatment failures. Gastroenterol Res Pract 2012;2012:484591.
40. Dresner D, Coyle W, Nemec R, Peterson R, Duntemann T, Lawson JM. Efficacy of ciprofloxacin in the eradication of Helicobacter pylori. South Med J 1996;89:775-8. (Pubitemid 26286678)
41. Jobe BA, Grasley A, Deveney KE, Deveney CW, Sheppard BC. Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg 1995;169:480-3.
42. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007;3: CD004610.
43. Silva FM, Eisig JN, Chehter EZ, Silva JJ, Laudanna AA. Omeprazole, furazolidone, and tetracycline: an eradication treatment for resistant H. pylori in Brazilian patients with peptic ulcer disease. Rev Hosp Clin Fac Med Sao Paulo 2002;57:205-8.
44. Mansour-Ghanaei F, Fallah MS, Shafaghi A. Eradication of Helicobacter pylori in duodenal ulcer disease tetracycline & furazolidone vs. metronidazole & amoxicillin in omeprazole based triple therapy. Med Sci Monit 2002;8: PI27-30. (Pubitemid 34263059)
45. Zullo A, Ierardi E, Hassan C, De Francesco V. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi J Gastroenterol 2012;18:11-7. (Pubitemid 46723156)
46. Ahmed HH, El-Aziem SH, Abdel-Wahhab MA. Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats. Toxicology 2008;243:31-42. (Pubitemid 350253131)
47. Jin X, Tang S, Chen Q, et al. Furazolidone induced oxidative DNA damage via up-regulating ROS that caused cell cycle arrest in human hepatoma G2 cells. Toxicol Lett 2011;201:205-12.
48. Boyanova L, Gergova G, Nikolov R, et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Micrbiol Infect Dis 2008;60:409-15. (Pubitemid 351380781)
49. Alarcon T, de la Obra P, Domingo D, Garcia-Campos JA, Diaz-Reganon J, Lopez-Brea M. In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate. Rev Esp Quimioter 2005;18:313-8.
50. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracyclinecomparison of three 3-year studies. Arch Iran Med 2010;13:177-87.
51. Su ZL, Xu HX, Zhang CY, et al. Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance. Croat Med J 2006;47:410-5.
52. Godoy A P O, Ribeiro ML, Benvengo Y H B, et al. Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol 2003;3:20-6.
53. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000;95:2688-91.
54. Hunt RH, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011;20:299-304.
55. Heep M, Lehn N, Brandstatter B, Rieger U, Senzenberger S, Wehrl W. Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002;21:143-5. (Pubitemid 34212221)
56. Glocker E, Bogdan C, Kist M. Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany. J Antimicrob Chemother 2007;59:874-9. (Pubitemid 47073357)
57. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012;35:209-21.
58. Nishizawa T, Suzuki H, Matsuzaki J, et al. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrob Agents Chemother 2011;55:5374-5.
59. Aboderin OA, Abdu AR, Odetoyin B, et al. Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. Afr Health Sci 2007;7:143-7.
60. Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrobial Chemother 2012;67:170-3.
61. Chung JW, Lee GH, Jeong JY, et al. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol 2012;27:493-7.
62. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009;14:61-5.
63. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul. South Korea. Antimicrob Agents Chemother 2004;48:4843-7. (Pubitemid 39577692)
64. Wenzhen Y, Yumin L, Quanlin G, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori Infection?-Meta-analysis of randomized controlled trials. Intern Med 2010;49:1103-9.
65. Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 2005;10:363-72. (Pubitemid 41368693)
66. Chisholm SA, Owen RJ. Frequency and molecular characteristics of ciprofloxacin-and rifampicin-resistant Helicobacter pylori from gastric infections in the UK. J Med Microbiol 2009;58:1322-8.